Oncologist-approved cancer information from the American Society of Clinical Oncology
Printer Friendly
Download PDF

Gestational Trophoblastic Tumor

This section has been reviewed and approved by the Cancer.Net Editorial Board, 1/2012

Overall, GTTs are rare. In the United States, GTTs account for less than 1% of all cancers that start in a woman's reproductive system (a grouping called gynecologic cancers). A hydatidiform mole may develop in one in 1,000 pregnancies, and 15% of these cases become cancerous (malignant).

Choriocarcinoma is very rare, occurring in about two to seven pregnancies out of 100,000 in the United States. Molar pregnancies occur much more often in Asian and African countries than in the United States.

GTTs are typically curable, especially if found early.

Cancer statistics should be interpreted with caution. These estimates are based on data from thousands of women with this type of cancer in the United States, but the actual risk for a particular individual may differ. It is not possible to tell a woman how long she will live with a GTT. Learn more about understanding statistics.

Statistics source: American Cancer Society.

Last Updated: 
Wednesday, February 26, 2014

© 2005-2014 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

Connect With Us: